METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C
Go back to METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C| (NASDAQ: NVCR) | Delayed: 16.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.72 | 52 Week High | $28.95 | |||
| Open | $16.72 | 52 Week Low | $5.95 | |||
| Day High | $16.72 | P/E | N/A | |||
| Day Low | $16.72 | EPS | $0.00 | |||
| Volume | 2,983 | |||||
